Literature DB >> 10757415

In-vivo and in-vitro evidence of a carrier-mediated efflux transport system for oestrone-3-sulphate across the blood-cerebrospinal fluid barrier.

T Kitazawa1, K Hosoya, T Takahashi, Y Sugiyama, T Terasaki.   

Abstract

The efflux transport of oestrone-3-sulphate, a steroid hormone sulphate, across the blood-cerebrospinal fluid barrier has been examined following its intracerebroventricular administration. [3H]Oestrone-3-sulphate was eliminated from cerebrospinal fluid (CSF) with an apparent efflux clearance of 205 microL min(-1) per rat. There was 25% of unmetabolized [3H]oestrone-3-sulphate in the plasma 5 min after intracerebroventricular administration, indicating that at least a part of [3H]oestrone-3-sulphate is transported from CSF to the circulating blood across the blood-CSF barrier. This efflux transport was inhibited by co-administration of excess oestrone-3-sulphate (25 mM 10 microL = 0.25 micromol) into rat cerebral ventricle. To characterize the oestrone-3-sulphate transport process, an in-vitro uptake experiment was performed using isolated rat choroid plexus. Oestrone-3-sulphate uptake by isolated rat choroid plexus was found to be a saturable process with a Michaelis-Menten constant (Km) of 18.1 +/- 6.3 microM, and a maximum uptake rate (Vmax) of 48.0 +/- 15.1 pmol min(-1) microL(-1) of tissue. The oestrone-3-sulphate transport process was temperature dependent and was inhibited by metabolic inhibitors such as 2,4-dinitrophenol and rotenone, suggesting an energy dependence. This uptake process was also inhibited by steroid hormone sulphates (1 mM dehydroepiandrosterone sulphate and 1 mM oestrone sulphate), bile acids (1 mM taurocholic acid and 1 mM cholic acid) and organic anions (1 mM sulphobromophthalein and 1 mM phenolsulphonphthalein), whereas 1 mM p-aminohippuric acid, 1 mM p-nitrophenol sulphate, 0.1 mM methotrexate and the cardiac glycoside, 2.5 microM digoxin, had little effect. In conclusion, these results provide evidence that oestrone-3-sulphate is transported from CSF to the circulating blood across the blood-CSF barrier via a carrier-mediated efflux transport system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757415     DOI: 10.1211/0022357001773968

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  5 in total

1.  Characterization of the amino acid transport of new immortalized choroid plexus epithelial cell lines: a novel in vitro system for investigating transport functions at the blood-cerebrospinal fluid barrier.

Authors:  T Kitazawa; K Hosoya; M Watanabe; T Takashima; S Ohtsuki; H Takanaga; M Ueda; N Yanai; M Obinata; T Terasaki
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

2.  Different distribution of morphine and morphine-6 beta-glucuronide after intracerebroventricular injection in rats.

Authors:  Takashi Okura; Masanori Saito; Misato Nakanishi; Noriyuki Komiyama; Aki Fujii; Shizuo Yamada; Ryohei Kimura
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

3.  Expression and functional involvement of organic anion transporting polypeptide subtype 3 (Slc21a7) in rat choroid plexus.

Authors:  Hiroyuki Kusuhara; Zhonggui He; Yoshinori Nagata; Yoshitane Nozaki; Takashi Ito; Hiroyuki Masuda; Peter J Meier; Takaaki Abe; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

4.  Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: relevance to neural disorders.

Authors:  Masanori Tachikawa; Ken-Ichi Hosoya
Journal:  Fluids Barriers CNS       Date:  2011-02-28

5.  Thyroxine transfer from cerebrospinal fluid into choroid plexus and brain is affected by brefeldin A, low sodium, BCH, and phloretin, in ventriculo-cisternal perfused rabbits.

Authors:  Kazem Zibara; Ali El-Zein; Wissam Joumaa; Mohammad El-Sayyad; Stefania Mondello; Nouhad Kassem
Journal:  Front Cell Dev Biol       Date:  2015-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.